Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Non-Small Cell Lung Cancer
Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC
The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.
Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC
A PDUFA target date of November 24, 2022 has been set for the application.
Study Reveals Lack of Adherence to Treatment Guidelines in Non-Small Cell Lung Cancer
Patient age, treatment center, and tumor size were associated with a lack of adherence.
- Loading...
Loading...
Next post in News
Loading... 
Loading...